3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
pembrolizumab
1019
Carboplatin
959
Paclitaxel
932
Gemcitabine
793
Cisplatin
748
Docetaxel
682
Bevacizumab
610
Pemetrexed
502
Nivolumab
486
Cyclophosphamide
466
Capecitabine
461
Fluorouracil
417
Dexamethasone
402
Rituximab
372
Oxaliplatin
347
Injections
342
atezolizumab
297
Trastuzumab
297
Leucovorin
286
Cetuximab
282
Irinotecan
266
130-nm albumin-bound paclitaxel
252
Prednisone
244
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
Fulvestrant
217
fludarabine
214
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
VP-102
×
Clear all
NCT07246590
2026-01-21
COVE-2
Verrica Pharmaceuticals Inc.
Phase 3
Recruiting
300 enrolled
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts